C L A I M S

1. A conjugated molecule comprising a peptide having at least 80% amino acid sequence identity to SEQ ID NO: 1 or SEQ ID NO: 9 and displaying at least 0.1 % activity of native glucagon-like peptide 1 (GLP-1) at the GLP-1 receptor, and an *N*-methyl-D-aspartate receptor (NMDAR) antagonist selected from the list consisting of memantine, memantine hydrochloride, amantadine, ketamine, phencyclidine (PCP), MK801, norketamin, and neramexane, the peptide being covalently bonded to the NMDAR antagonist either directly or through a chemical linker.

2. The conjugated molecule according to claim 1, wherein the peptide consists of at least 10 amino acids and no more than 60 amino acids.

3. The conjugated molecule according to any one of the preceding claims, wherein the NMDAR antagonist is covalently bonded at the C-terminal region of the peptide.

4. The conjugated molecule according to any one of the preceding claims, wherein the NMDAR antagonist is covalently bonded to the peptide via a cleavable chemical linker, the cleavable chemical linker being selected from acid-cleavable linkers, enzyme-cleavable linkers, peptide-cleavable linkers, and linkers comprising a disulfide group.

5. The conjugated molecule according to claim 4, wherein the chemical linker has the formula R_1-R_3-S-S-R_4-R_5-O-CO-R_2, wherein R_1 is the peptide, R_2 the NMDAR antagonist, R_3 is optional and when present is selected from $C(CH_3)_2$, CH_2-CH_2, or CH_2, bonded to a side chain of the peptide or to a carbon atom of the backbone chain of the peptide, R_4 is $(CH_2)_n$ or C_6H_4, R_5 is optional and when present is selected from $C(CH_3)_2$, CH_2-CH_2, or CH_2, and n is 1, 2, 3 or 4.

6. The conjugated molecule according to any one of the preceding

claims for use in therapy.

7. Use of the conjugated molecule according to any one of the claims 1 to 6 in the manufacture of a medicament for the treatment of obesity, binge eating disorder, insulin resistance, type 2 diabetes, dyslipidaemia, non-alcoholic steatohepatitis, or non-alcoholic fatty liver disease.

8. A pharmaceutical composition comprising the conjugated molecule according to any one of the claims 1 to 6 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

9. A non-therapeutic treatment of mammals for reducing body weight, which comprises orally administering to said mammal the conjugated molecule according to any one of the claims 1 to 6.

10. The non-therapeutic treatment of mammals for reducing body weight according to claim 9, wherein the mammal has a non-pathogenic body mass index (BMI) of up to 30 kg/m^2.